alexa Left Ventricular Hypertrophy | UK| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Left Ventricular Hypertrophy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Left Ventricular Hypertrophy

    Left Ventricular hypertrophy is outlined as an increase in the mass of the left ventricle, which may also be secondary to an expand in wall thickness, and broaden in cavity measurement. Left ventricular hypertrophy more often than not develops steadily. Whilst ventricular hypertrophy happens naturally as a response to aerobic undertaking and strength coaching, it is most commonly known as a pathological response to cardiovascular disorder, or high blood stress.

  • Left Ventricular Hypertrophy

     Treatment for LVH focuses on the underlying the cause of the condition. Depending on the cause, Treatment may include medication or surgery. Doctor suggests the treatment for LVH such as regular exercise a low-sodium, low-fat diet and no smoking. They used to control the blood pressure by using some types of drugs like enalapril (Vasotec), lisinopril (Prinivil, Zestril) and captopril (Capoten), atenolol (Tenormin), carvedilol (Coreg), metoprolol (Toprol XL) and bisoprolol (Zebeta) and etc.

  • Left Ventricular Hypertrophy

    We evaluated 21 hypertensive patients with electrocardiographic LVH in the LIFE study and 8 normal controls using 3D MR tagging and echocardiography. Patients had higher MR LV mass than normals (116 ± 40 versus 63 ± 6 g/m2, P = 0.002). Neither echocardiographic fractional shortening (32 ± 6 versus 33% ± 3%), LVEF (63% versus 64%) or mean end-systolic stress (175 ± 27 versus 146 ± 28 g/cm2) were significantly different, yet global MWCS was decreased by both echocardiography (13.4 ± 2.8 versus 18.2% ± 1.5%, P < 0.001) and MR (16.8 ± 3.6 versus 21.6% ± 3.0%, P < 0.005).

Speaker PPTs


High Impact List of Articles

Conference Proceedings